| 2024-09-05 |
[In Focus] Nocebo, gut disorders, and diet |
Heidi M Staudacher, Leena T Putkonen |
|
| 2024-09-05 |
[Review] Natural history and progression of metabolic dysfunction-associated steatotic liver disease |
Hannes Hagström, Ying Shang, Hannes Hegmar, Patrik Nasr |
|
| 2024-09-05 |
[In Focus] Irritable bowel syndrome: an urgent issue |
Chrissie Pearson |
|
| 2024-09-05 |
[Correspondence] Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply |
Eduard A van Bodegraven, Alberto Balduzzi, Tess M E van Ramshorst, Giuseppe Malleo, Frederique L Vissers, Jony van Hilst, Giovanni Marchegiani, Matteo de Pastena, Roberto Salvia, Casper H J van Eijck, Marc G Besselink, Dutch Pancreatic Cancer Group |
|
| 2024-09-05 |
[News] Research in Brief |
Holly Baker |
|
| 2024-09-05 |
[Comment] Augmenting colonoscopy with AI: insights and future directions |
Sravanthi Parasa |
|
| 2024-09-05 |
[Correspondence] Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? |
Yuan Sun, Yan Li, Kezhen Zong, Ning Jiang, Baoyong Zhou |
|
| 2024-09-05 |
[Editorial] Blood tests for colorectal cancer: practical or premature? |
The Lancet Gastroenterology & Hepatology |
|
| 2024-09-05 |
[Articles] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial |
Klara Dorman, Stefan Boeck, Karel Caca, Maximilian Reichert, Thomas J Ettrich, Helmut Oettle, Oliver Waidmann, Dominik P Modest, Lothar Müller, Patrick Michl, Stephan Kanzler, Daniel Pink, Anke Reinacher-Schick, Michael Geißler, Henning Pelz, Volker Kunzm |
|
| 2024-09-05 |
[Comment] Metastatic pancreatic cancer: a new standardised dose-reduction regimen? |
Paula Ghaneh, Daniel Palmer |
|
| 2024-09-05 |
[Articles] Polyp detection with colonoscopy assisted by the GI Genius artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, pragmatic randomised |
Alexander Seager, Linda Sharp, Laura J Neilson, Andrew Brand, James S Hampton, Tom J W Lee, Rachel Evans, Luke Vale, John Whelpton, Nathania Bestwick, Colin J Rees, COLO-DETECT trial team |
|
| 2024-09-05 |
[Articles] Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trial |
Robin A Faber, Ruben P J Meijer, Daphne H M Droogh, Jasmijn J Jongbloed, Okker D Bijlstra, Fran Boersma, Jeffrey P B M Braak, Elma Meershoek-Klein Kranenbarg, Hein Putter, Fabian A Holman, J Sven D Mieog, Peter A Neijenhuis, Esther van Staveren, Johanne G |
|
| 2024-09-05 |
[Comment] The promise of indocyanine green in colorectal surgery |
Zoe Garoufalia |
|
| 2024-09-05 |
[Personal View] Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions |
Ryan J Jalleh, Chris K Rayner, Trygve Hausken, Karen L Jones, Michael Camilleri, Michael Horowitz |
|
| 2024-09-05 |
[Comment] The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease |
Nurulamin M Noor, Shaji Sebastian, Miles Parkes, Tim Raine |
|
| 2024-09-05 |
[Comment] Breaking down barriers between liver, addiction, and mental health services for people with alcohol-related liver disease |
Ashwin D Dhanda, Victoria Allgar, Neeraj Bhala, Lynne Callaghan, Joana Castro, Shilpa Chokshi, Amanda Clements, Colin Drummond, Ewan H Forrest, Lesle Manning, Richard Parker, Debbie L Shawcross, Jennifer Towey |
|
| 2024-08-08 |
[Correspondence] Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer |
Changjing Cai, Peng Zhang, Ying Han, Hong Shen, Shan Zeng |
|
| 2024-08-08 |
[Editorial] Global progress towards alcohol harm reduction insufficient |
The Lancet Gastroenterology & Hepatology |
|
| 2024-08-08 |
[In Focus] Normothermic regional perfusion presents ethical concerns in the USA |
Bryant Furlow |
|
| 2024-08-08 |
[Correspondence] Diet or optimised medical therapy for people with irritable bowel syndrome |
Christian Lambiase, Giuseppe Chiarioni, Massimo Bellini |
|
| 2024-08-08 |
[Correspondence] Diet or optimised medical therapy for people with irritable bowel syndrome – Authors' reply |
Sanna Nybacka, Hans Törnblom, Axel Josefsson, Johann P Hreinsson, Lena Böhn, Åsa Frändemark, Cecilia Weznaver, Stine Störsrud, Magnus Simrén |
|
| 2024-08-08 |
[Comment] Expression of concern—Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis |
The Editors of The Lancet Gastroenterology & Hepatology |
|
| 2024-08-08 |
[Correspondence] Diet or optimised medical therapy for people with irritable bowel syndrome |
Alexander C Ford, Christopher J Black, Michael Camilleri |
|
| 2024-08-08 |
[Comment] Watch and wait for rectal cancer: towards data-informed surveillance |
Fahima Dossa, Martin R Weiser |
|
| 2024-08-08 |
[Comment] Optimising local treatment decisions for rectal cancer |
Krishan R Jethwa, Khush S Aujla, Aurelie Garant |
|
| 2024-08-08 |
[In Focus] A breakdown of the gut |
Genevieve Pascal |
|
| 2024-08-08 |
[News] Research in brief |
Holly Baker |
|
| 2024-08-08 |
[Correspondence] Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply |
Durgesh Wankhede, Michael Hoffmeister |
|
| 2024-08-08 |
[Editorial] Viral hepatitis: time for action |
The Lancet Gastroenterology & Hepatology |
|
| 2024-08-08 |
[Articles] Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial |
Kate Wooldrage, Emma C Robbins, Stephen W Duffy, Amanda J Cross |
|
| 2024-08-08 |
[Comment] Brief sigmoidoscopy provides 21-year colorectal cancer risk reduction in men |
Michael Bretthauer, Nastazja D Pilonis |
|
| 2024-08-08 |
[Articles] An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial |
Oswaldo Ortiz, Maria Daca-Alvarez, Liseth Rivero-Sanchez, Antonio Z Gimeno-Garcia, Marta Carrillo-Palau, Victoria Alvarez, Alejandro Ledo-Rodriguez, Luigi Ricciardiello, Chiera Pierantoni, Robert Hüneburg, Jacob Nattermann, Raf Bisschops, Sabine Tejpar, A |
|
| 2024-08-08 |
[Comment] Artificial intelligence-assisted adenoma detection in people with Lynch syndrome |
Carol A Burke, Carole Macaron, Aparajita Singh |
|
| 2024-08-08 |
[Articles] Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021 |
GBD 2021 Appendicitis Collaborator Group |
|
| 2024-08-08 |
[News] Hepatitis C epidemic among Rohingya refugees in Cox's Bazar: a public health emergency |
Udani Samarasekera |
|
| 2024-08-08 |
[Articles] Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial |
Eline M L van der Does de Willebois, Vittoria Bellato, Marjolijn Duijvestein, Jarmila D W van der Bilt, Koen van Dongen, Antonino Spinelli, Geert R D'Haens, Marco W Mundt, Federica Furfaro, Silvio Danese, Andrea Vignali, Willem A Bemelman, Christianne J B |
|
| 2024-08-08 |
[Comment] Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand? |
Benjamin Click, Stefan D Holubar |
|
| 2024-08-08 |
[Review] Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies |
Laure Elkrief, Virginia Hernandez-Gea, Marco Senzolo, Agustin Albillos, Anna Baiges, Annalisa Berzigotti, Christophe Bureau, Sarwa Darwish Murad, Andrea De Gottardi, François Durand, Juan-Carlos Garcia-Pagan, Ton Lisman, Mattias Mandorfer, Valérie McLin, |
|
| 2024-08-08 |
[Review] Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework |
Renée Duijzer, Lucas H P Bernts, Anja Geerts, Bart van Hoek, Minneke J Coenraad, Chantal Rovers, Domenico Alvaro, Ed J Kuijper, Frederik Nevens, Jan Halbritter, Jordi Colmenero, Juozas Kupcinskas, Mahdi Salih, Marie C Hogan, Maxime Ronot, Valerie Vilgrain |
|
| 2024-07-04 |
[In Focus] Saturated Facts: the start of a preventive revolution? |
Elizabeth Haslam |
|
| 2024-07-04 |
[News] EASL Congress 2024 |
Rob Brierley |
|
| 2024-07-04 |
[Correspondence] Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply |
Florentine E F Timmer, Bart Geboers, Hester J Scheffer, Anna M E Bruynzeel, Martijn R Meijerink, CROSSFIRE study investigators |
|
| 2024-07-04 |
[Correspondence] Time for a treat all approach for hepatitis B |
Rachel Halford, Danjuma Adda, Jessica Hicks, Cary James, Alexandra Smith |
|
| 2024-07-04 |
[News] Research in Brief |
Holly Baker |
|
| 2024-07-04 |
[Correspondence] Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial |
Jasmijn Maria Westerhoff, Nina Niu Sanford, William Adrian Hall |
|
| 2024-07-04 |
[News] Digestive Disease Week 2024 |
Hugh Thomas |
|
| 2024-07-04 |
[Articles] Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, doubl |
Yoon-Koo Kang, Masanori Terashima, Young-Woo Kim, Narikazu Boku, Hyun Cheol Chung, Jen-Shi Chen, Jiafu Ji, Ta-Sen Yeh, Li-Tzong Chen, Min-Hee Ryu, Jong Gwang Kim, Takeshi Omori, Sun Young Rha, Tae Yong Kim, Keun Won Ryu, Shinichi Sakuramoto, Yasunori Nish |
|
| 2024-07-04 |
[Comment] Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma |
Maeve A Lowery |
|
| 2024-07-04 |
[Articles] Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study |
Harry L A Janssen, Young-Suk Lim, Pietro Lampertico, Jeong Heo, Chi-Yi Chen, Claire Fournier, Tak Yin Owen Tsang, Ho Bae, Chien-Hung Chen, Carla S Coffin, Sang Hoon Ahn, Huy Trinh, John F Flaherty, Frida Abramov, Yang Zhao, Yang Liu, Audrey Lau, Polina Ge |
|
| 2024-07-04 |
[Comment] Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B |
Lung-Yi Mak |
|
| 2024-07-04 |
[Editorial] No accident: the UK infected blood scandal |
The Lancet Gastroenterology & Hepatology |
|
| 2024-07-04 |
[Articles] Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open- |
Arndt Vogel, Anna Saborowski, Patrick Wenzel, Henning Wege, Gunnar Folprecht, Albrecht Kretzschmar, Philipp Schütt, Lutz Jacobasch, Nicolas Ziegenhagen, Stefan Boeck, Danmei Zhang, Stephan Kanzler, Sebastian Belle, Johannes Mohm, Eray Gökkurt, Christian L |
|
| 2024-07-04 |
[Comment] Nanoliposomal irinotecan in advanced biliary tract cancers |
David Malka, Raphaël Colle |
|
| 2024-07-04 |
[Comment] Considerations for treating autistic individuals in gastroenterology clinics |
Timothy Buie, Kara Margolis |
|
| 2024-07-04 |
[Articles] Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study |
Do-Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li-Tzong Chen, Masayuki Kitano, Choong-kun Lee, Jin Won Kim, Ming-Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen-Shi Chen, Piotr Potemski, Howard A Burris, |
|
| 2024-07-04 |
[Comment] Immunotherapy in biliary tract cancer: are we finally on the right path? |
Angela Dalia Ricci, Alessandro Rizzo, Claudio Lotesoriere |
|
| 2024-07-04 |
[Review] Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease |
Marietta Iacucci, Giovanni Santacroce, Irene Zammarchi, Yasuharu Maeda, Rocío Del Amor, Pablo Meseguer, Bisi Bode Kolawole, Ujwala Chaudhari, Antonio Di Sabatino, Silvio Danese, Yuichi Mori, Enrico Grisan, Valery Naranjo, Subrata Ghosh |
|
| 2024-07-04 |
[Review] Infections in cirrhosis |
Salvatore Piano, Chalermrat Bunchorntavakul, Sebastian Marciano, K Rajender Reddy |
|
| 2024-06-11 |
[Correspondence] The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply |
Qu Liu, Rong Liu |
|
| 2024-06-11 |
[Editorial] Direct-to-consumer microbiome testing needs regulation |
The Lancet Gastroenterology & Hepatology |
|
| 2024-06-11 |
[Correspondence] Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial |
Rirong Chen, Shenghong Zhang |
|
| 2024-06-11 |
[Correspondence] Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial |
Vinay Borkar, Yatin Lunagariya, Shivani Chopra, Deepak Sasikumar, Meghraj Ingle |
|
| 2024-06-11 |
[Correspondence] Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial |
Jack Satsangi, Jan Nowak, Rahul Kalla, Jean-Frederic Colombel |
|
| 2024-06-11 |
[Correspondence] Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial |
Arno R Bourgonje, Marijn C Visschedijk, Eleonora A M Festen, Rinse K Weersma, Gerard Dijkstra |
|
| 2024-06-11 |
[Correspondence] The HEPSANET score to assess treatment eligibility of chronic hepatitis B in Africa – Authors' reply |
Nicolas Minier, Asgeir Johannessen, Roger Sombié, Maud Lemoine, Yusuke Shimakawa |
|
| 2024-06-11 |
[Correspondence] The HEPSANET score to assess treatment eligibility of chronic hepatitis B in Africa |
Jian Wang, Shaoqiu Zhang, Chao Jiang, Chao Wu, Rui Huang |
|
| 2024-06-11 |
[Correspondence] Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial – Authors' reply |
Nurulamin M Noor, James C Lee, Simon Bond, Miles Parkes |
|
| 2024-06-11 |
[Correspondence] Resmetirom for MASH-related cirrhosis |
Gong Feng, Virginia Hernandez-Gea, Ming-Hua Zheng |
|
| 2024-06-11 |
[Corrections] Correction to Lancet Gastroenterol Hepatol 2024; 9: 34–44 |
|
|
| 2024-06-11 |
[In Focus] Chronic Boom |
Joe Moody |
|
| 2024-06-11 |
[In Focus] Blood Matters |
Fiyinfolu Deborah Oyekan |
|
| 2024-06-11 |
[News] Research in Brief |
Holly Baker |
|
| 2024-06-11 |
[In Focus] The Mediterranean diet for gastrointestinal conditions—premature or panacea? |
Heidi M Staudacher, Elena S George |
|
| 2024-06-11 |
[Corrections] Correction to Lancet Gastroenterol Hepatol 2024; 9: 620–31 |
|
|
| 2024-06-11 |
[Comment] Providing trauma-informed care for all in gastroenterology |
Christina H Jagielski, Alexandra Fuss, Tiffany H Taft |
|
| 2024-06-11 |
[Correspondence] The role of ERAS in robotic pancreaticoduodenectomy |
Dimitrios Moris, Sabino Zani |
|
| 2024-06-11 |
[Articles] Duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy in Ontario, Canada: a population-based cohort study |
Arlinda Ruco, Rahim Moineddin, Rinku Sutradhar, Jill Tinmouth, Qing Li, Linda Rabeneck, M Elisabetta Del Giudice, Catherine Dubé, Nancy N Baxter |
|
| 2024-06-11 |
[Comment] Negative screening colonoscopy and long-term colorectal cancer risk—is it time to extend the screening interval? |
J E G IJspeert, M E van Leerdam |
|
| 2024-06-11 |
[Articles] Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis |
Durgesh Wankhede, Tanwei Yuan, Matthias Kloor, Niels Halama, Hermann Brenner, Michael Hoffmeister |
|
| 2024-06-11 |
[Comment] Rethinking colorectal cancer prognosis: beyond microsatellite status |
Elisabetta Fenocchio |
|
| 2024-06-11 |
[Articles] Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial |
Alexander G Miethke, Adib Moukarzel, Gilda Porta, Joshue Covarrubias Esquer, Piotr Czubkowski, Felipe Ordonez, Antonella Mosca, Amal A Aqul, Robert H Squires, Etienne Sokal, Daniel D'Agostino, Ulrich Baumann, Lorenzo D'Antiga, Nagraj Kasi, Nolwenn Laborde |
|
| 2024-06-11 |
[Review] Targeting the EGFR signalling pathway in metastatic colorectal cancer |
Stefania Napolitano, Giulia Martini, Davide Ciardiello, Sara Del Tufo, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello |
|
| 2024-06-11 |
[Articles] Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial |
Nadia Ovchinsky, Madeleine Aumar, Alastair Baker, Ulrich Baumann, Philip Bufler, Mara Cananzi, Piotr Czubkowski, Özlem Durmaz, Ryan Fischer, Giuseppe Indolfi, Wikrom W Karnsakul, Florence Lacaille, Way S Lee, Giuseppe Maggiore, Philip Rosenthal, Mathias R |
|
| 2024-06-11 |
[Review] Pathophysiology and therapeutic options for cirrhotic portal hypertension |
Sergi Guixé-Muntet, Sergio Quesada-Vázquez, Jordi Gracia-Sancho |
|
| 2024-05-09 |
[Correspondence] People living in prison must be included in country monitoring systems to accurately assess HCV elimination progress |
Lara Tavoschi, Nicola Cocco, Filipa Alves da Costa, Andrey R Lloyd, Stuart A Kinner |
|
| 2024-05-09 |
[Correspondence] Covered versus bare-metal stenting in chronic mesenteric ischaemia – Authors' reply |
Luke G Terlouw, Louisa J D van Dijk, Desirée van Noord, Marco J Bruno |
|
| 2024-05-09 |
[Correspondence] Haematopoietic stem-cell transplantation in Crohn's disease |
Akshita Gupta, Daniela Guisado, Elena Ricart, Jean-Frederic Colombel, Louis Cohen |
|
| 2024-05-09 |
[News] Research in Brief |
Holly Baker |
|
| 2024-05-09 |
[Correspondence] Covered versus bare-metal stenting in chronic mesenteric ischaemia |
Lorenzo Garzelli, Iannis Ben Abdallah, Maxime Ronot |
|
| 2024-05-09 |
[In Focus] Liver transplants: a different kind of theatre |
Peter Ranscombe |
|
| 2024-05-09 |
[In Focus] Our Lives with IBD |
Jennifer Thorley |
|
| 2024-05-09 |
[Correspondence] Equity in clinical trials for hepatitis B |
Tim Mitchell, Jeremy S Nayagam, Mzamo N Mbelle, Kenneth Kabagambe, Kosh Agarwal |
|
| 2024-05-09 |
[Corrections] Correction to Lancet Gastroenterol Hepatol 2024; 9: 507–20 |
|
|
| 2024-05-09 |
[News] Scottish Parliament votes to increase minimum unit price for alcohol |
Udani Samarasekera |
|
| 2024-05-09 |
[Editorial] Urgent action needed to achieve viral hepatitis elimination |
The Lancet Gastroenterology & Hepatology |
|
| 2024-05-09 |
[Articles] A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial |
Sanna Nybacka, Hans Törnblom, Axel Josefsson, Johann P Hreinsson, Lena Böhn, Åsa Frändemark, Cecilia Weznaver, Stine Störsrud, Magnus Simrén |
|
| 2024-05-09 |
[Comment] Managing irritable bowel syndrome: balancing diet and pharmacotherapy |
Uday C Ghoshal, Uzma Mustafa, Mahesh K Goenka |
|
| 2024-05-09 |
[Articles] Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study |
Neil Chanchlani, Simeng Lin, Claire Bewshea, Benjamin Hamilton, Amanda Thomas, Rebecca Smith, Christopher Roberts, Maria Bishara, Rachel Nice, Charlie W Lees, Shaji Sebastian, Peter M Irving, Richard K Russell, Timothy J McDonald, James R Goodhand, Tariq |
|
| 2024-05-09 |
[Comment] PANTS extension study: how best to use anti-TNF drugs in Crohn's disease |
Gareth C Parkes, Charlotte R H Hedin |
|
| 2024-05-09 |
[Comment] WHO 2024 hepatitis B guidelines: an opportunity to transform care |
Philippa J Easterbrook, Niklas Luhmann, Sahar Bajis, Myat Sandi Min, Morkor Newman, Olufunmilayo Lesi, Meg C Doherty |
|
